An alpha-synuclein antibody in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that accumulate in the nerve cells of patients with PD and appear to spread throughout the nervous system during the progression of the disease.
These insights support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, prevent their formation, or stop them from spreading. Such therapies could potentially prevent or delay the onset of PD, or halt or slow its progression. An alpha-synuclein antibody is an antibody that is differentiated by its high affinity, high selectivity, and reduced effector function (lower interaction with the immune system), which…
